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ARTICLE
Fine mapping of MHC region in lung cancer
highlights independent susceptibility loci by
ethnicity
Aida Ferreiro-Iglesias et al.#
Lung cancer has several genetic associations identiﬁed within the major histocompatibility
complex (MHC); although the basis for these associations remains elusive. Here, we analyze
MHC genetic variation among 26,044 lung cancer patients and 20,836 controls densely
genotyped across the MHC, using the Illumina Illumina OncoArray or Illumina 660W SNP
microarray. We impute sequence variation in classical HLA genes, ﬁne-map MHC associa-
tions for lung cancer risk with major histologies and compare results between ethnicities.
Independent and novel associations within HLA genes are identiﬁed in Europeans including
amino acids in the HLA-B*0801 peptide binding groove and an independent HLA-DQB1*06 loci
group. In Asians, associations are driven by two independent HLA allele sets that both
increase risk in HLA-DQB1*0401 and HLA-DRB1*0701; the latter better represented by the
amino acid Ala-104. These results implicate several HLA–tumor peptide interactions as the
major MHC factor modulating lung cancer susceptibility.
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Large scale genome wide association studies (GWAS) of lungcancer revealed different susceptibility loci across the mainhistological subtypes: adenocarcinoma (AD), squamous cell
carcinoma (SCC), and small cell lung cancer (SCLC)1,2. This
heterogeneity is particularly apparent for the Major Histo-
compatibility Complex (MHC), where associations have been
observed speciﬁcally for SCC at 6p21.33 (rs3117582) in
Europeans3,4, and for AC at 6p21.32 (rs2395185) in Asians5.
However, interpreting MHC associations is difﬁcult as it is the
most gene-dense region of the genome, is highly polymorphic,
displays extensive linkage disequilibrium (LD), and genes are
clustered by related functions6. In addition, this extreme variation
is known to be shaped by population history and different
infectious exposures7,8. Imputation of classical Human Leukocyte
Antigen (HLA) at a four-digit resolution based on high-density
SNP genotyping is an accurate and fast alternative to traditional
HLA genotyping and permits the screening of large sample sets of
different ethnicities9,10.
Understanding the role of HLA in lung cancer is important, as
it may help to elucidate the causal aetiology beyond the pre-
dominant role of smoking. Class I and II HLA molecules are
known critical mediators in disease defense through presenting
intra- or extra-cellular peptides on the cell surface in a form that
can be recognized by the T cell receptors (TCR) and to then
activate a speciﬁc T cell response11. To avoid immune-mediated
elimination, cancer cells may lose their antigenicity due to dif-
ferent possibilities12. One is the immune selection of cancer cells
which lack or mutate immunogenic tumor antigens13. Therefore,
certain MHC alleles and polymorphisms may target particular
tumor antigens, resulting in the observed disease-speciﬁc asso-
ciations. A recent example is the association between an extended
HLA haplotype (HLA-DRB1*1301–HLA-DQA1*0103–HLA-
DQB1*0603) and protection against HPV associated oropharynx
cancer14, as well as cervical cancer15. These insights have the
potential to inform tumor-speciﬁc immune responses and thus to
be useful in developing immunotherapies. Tumor antigens can be
derived from viral proteins, proteins encoded by cancer-germline
genes, differentiation antigens and proteins arising from somatic
mutations or gene rearrangements16. Identifying polymorphisms
controlling expression of speciﬁc HLA molecules, affecting the
peptide binding groove or the contact surface with the TCR may
help to disentangle lung cancer MHC associations but also may
provide new insights into cancer risk and possible immunother-
apy targets12.
To this end, we analyze genetic variation in two populations of
European and Asian ancestry densely genotyped across the MHC
in relation to lung cancer risk. Our results suggest that the genetic
risk of the MHC region on lung cancer is different by population
and by histology which points to different exposures or
mechanisms interacting with HLA.
Results
Imputation of the HLA region. After completion of imputation
for the European and Asian series (18,924 cases/15,439 controls
and 2324 cases/1656 controls, respectively) (Table 1), the ﬁnal set
of imputed variants used in association analysis were of high
quality for Europeans, 92.5% of the variants had R2 ≥ 0.9, and
67.8% of the less common variants (MAF < 0.05) had R2 ≥ 0.9,
but overall quality was less apparent for Asians as 60.5% of the
total variants and 30.7% of the rare variants (MAF < 0.05) had
R2 ≥ 0.9 for Asians. However common variants were well imputed
(75% of the common variants and 98% of common HLA alleles
(MAF > 0.05) had R2 ≥ 0.9). Given our sample size in Asians, our
primary focus was on common variants for which the current
imputation is satisfactory.
We also performed a laboratory validation of the variants
identiﬁed by imputation using another genotyping platform,
Affymetrix Axiom exome array17, in a subset of 5742 individuals
from the European series. A separate laboratory validation was
not available for the Asian populations although we did replicate
our results among never smokers in an independent series and we
validated imputed HLA alleles using a completely different
imputation algorithm and reference panel. Statistical re-
imputation was done in a random 10% subset of the samples
(3000 European samples and 1000 Asian samples from
Oncoarray) using HIBAG18. The average concordance between
imputed genotypes and their validation results either from an
Table 1 Demographic characteristics of the participating studies after quality control ﬁlters
European ancestry Asian ancestry
Case no. (%) Control no. (%) Case no. (%) Control no. (%)
OncoArray studies- passed QC 18,924 15,439 2324 1656
Age
≤50 2098 (11.1) 2084 (13.5) 242 (10.4) 154 (9.3)
>50 16,801 (88.8) 13,306 (86.2) 2080 (89.5) 1502 (90.7)
Missing 25 (0.1) 49 (0.3) 2 (0.1) 0 (0)
Sex
Male 11,685 (61.7) 9240 (59.8) 1578 (67.9) 1070 (64.6)
Female 7236 (38.2) 6196 (40.1) 746 (32.1) 586 (35.4)
Missing 3 (0.02) 3 (0.02) 0 (0) 0 (0)
Smoking status
Never 1830 (9.7) 4870 (31.5) 815 (35.0) 668 (40.3)
Ever 16,682 (88.2) 10,219 (66.2) 1503 (64.7) 983 (59.4)
Current 9459 (50.0) 4285 (27.8) 986 (42.4) 739 (44.6)
Missing 412 (2.2) 350 (2.3) 6 (0.3) 5(0.3)
Histology
Adenocarcinoma 7088 (37.5) — 1192 (51.3) —
Squamous cell carcinoma 4581 (24.2) — 641 (27.6) —
Small cell carcinoma 190 (10.5) — 94 (4.0) —
Othersa 5265 (27.8) 397(17.1)
aLarge Cell, Bronchioloalveolar Carcinoma, Non-Small Cell Carcinoma, Carcinoids, Others or Missing
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alternative genotyping platform or re-imputation was >95% for
all variants (Supplementary Table 10 and 11).
The best-guess genotype dosages (R2 ≥ 0.7) for two- and four-
digit classical alleles, as well as amino acid polymorphisms and
SNPs in the MHC region were tested for association with overall
lung cancer and subtypes in European (Fig. 1 and Table 2) and
Asian ancestries (Fig. 2 and Table 3).
HLA region association analyses. Multiple association signals
were detected in Europeans within class I and class II regions for
lung cancer overall (Fig. 1a). Stratiﬁed analyses showed that these
associations were restricted to SCC (Fig. 1d) with little evidence of
associations for AD (Fig. 1b) and SCLC (Fig. 1c). In contrast,
MHC associations in Asians were less abundant in the overall
analyses (Fig. 2a), and after stratifying by major histologies we
observed the top association signals for lung AD (Fig. 2b).
Therefore, subsequent explanations for Europeans and Asians
will refer to SCC and AD results, respectively.
In Europeans, the most signiﬁcant allele was the GT allele of a
multiple nucleotide variation at Chr6: 31431982–31431983
(NCBI build 36), a complex variant affecting the ﬁrst and second
nucleotides of HLA-B codon 163 (OR= 1.20, p= 1.30 × 10−11;
Fig. 1d. 1). This allele codes for Thr-163 or Glu-163 in HLA-B.
Thus, the strongest MHC signal mapped to an amino acid change
resulting in a Thr-163 in HLA-B, which is part of the sequence of
the four-digit allele HLA-B *0801 that showed an equivalent
association (Table 2).
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Fig. 1 European regional association plots of variants in the MHC region and lung cancer overall and major histologies (a–d); plots of stepwise conditional
analyses for squamous cell carcinoma (d.1–d.3). Each panel on the left shows the association plot for each unconditioned analysis a lung cancer overall, b
adenocarcinoma, c small cell, d squamous cell carcinoma. The association for each locus used for conditioning is shown in green in each panel (d.1)
unconditioned, (d.2) conditioned on HLA-B*0801, (d.3) conditioned on HLA-B*0801 and HLA-DQB1*06. Detailed association results in Table 2 and
Supplementary Fig. 1. Circles represent –log10 (P values) for each binary marker using the imputed allelic dosage (between 0 and 2). The dashed black
horizontal lines represent the study-wide signiﬁcant threshold of P= 6 × 10−6. The physical positions of HLA genes on chromosome 6 are shown at the
bottom. The color of the circles indicates the type of marker; light blue—SNPs outside HLA genes, green—classical HLA alleles and red—amino acid
polymorphisms of the HLA genes; deep blue—SNP within HLA genes)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05890-2 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3927 | DOI: 10.1038/s41467-018-05890-2 | www.nature.com/naturecommunications 3
Other signals including HLA alleles were also detected across the
MHC (Table 2; Fig. 1d. 1). A stepwise conditional logistic
regression analysis was performed to identify variants that
independently inﬂuence lung SCC susceptibility in Europeans.
First, conditioning on HLA-B *0801, HLA-DQB1 *06 remained as
the highest peak (OR= 0.85, p= 3.05 × 10−8; Fig. 1d. 2), while
other variants were not signiﬁcant. In a second step, we included
both HLA-B *0801 and HLA-DQB1*06 as covariates in the analysis
and did not detect any remaining independent signals (Fig. 1d. 3).
In Asians from Oncoarray, we also observed several associations
along class I and class II (Fig. 2b. 1). The A allele of rs3129860
located in an intergenic region within HLA class II was the top
associated marker. As this SNP was highly correlated with HLA-
DQB1*0401 (r2= 0.75) and apparently not showing a potential
regulatory function, we used this allele in subsequent steps. After
conditioning on classical HLA-DQB1*0401 allele, HLA-DRB1*0701
remained as the most signiﬁcant signal (Fig. 2b. 2). When we
controlled for both alleles, rs2256919 (an HLA-A intronic variant)
remained associated (Figure 2b. 3). Finally, after controlling for
HLA-DQB1*0401, HLA-DRB1*0701 and rs2256919 no additional
variants remained associated with AD risk with a signiﬁcance
threshold (conditioned P > 6 × 10−6; Figure 2b. 4).
Results of the stratiﬁed analyses by histology and by smoking
status for each of the independent variants found in Europeans
and Asians are summarized in Supplementary Fig. 1. We
observed no signiﬁcant differences by smoking status for any of
the analyzed variants. However, AH8.1 showed a risk effect in the
overall analysis as well as in the smoking groups, but a protective
effect (OR= 0.88) in the never-smoking group which involved a
signiﬁcant heterogeneity (phet= 0.006, Supplementary Fig. 1a).
We wanted to explore further the impact of this effect in the
overall analysis by adding smoking as a covariate for AH8.1 and
related markers, but also for the rest of associations in both
ethnithities. As can be seen in Supplementary Tables 8 and 9,
results are extremely similar to the original results in Tables 2 and
3, indicating that adjustment by smoking makes little difference,
as expected. In consequence, we can consider all the associated
markers practically independent on smoking status.
No signiﬁcant result or trend was detected for the European
associated variants when we checked their association in Asians
or vice versa. A possible reason for certain alleles highlighted in
our analysis might be their different frequencies and meaning in
European and Asian populations (Tables 2 and 3; Supplementary
Tables 2 and 3). For example, European hits like class I alleles and
DQB1*06 are very rare in Asians (<2%) (Supplementary Table 2)
but common in Europeans (>10%) (Table 2). However, other
alleles showed similar frequencies (>10%) in both populations
even they were associated just in one. Statistical power
calculations (Supplementary Tables 12 and 13) showed that the
Asian set sample size was insufﬁcient for detecting some
European hits but not the opposite. This suggests ethnic-
speciﬁc effects due to population history although we cannot
discard the same effects in squamous cell carcinoma in both
populations. However, it seems that HLA is not playing a role in
adenocarcinoma in Europeans, unless the effects are hidden in
very rare variants
Haplotype analysis. Because of the broad LD of the region, we
wanted to assess the physical genetic boundaries of these asso-
ciations on the basis of haplotype patterns. Supplementary Figs. 2
and 3 include an overview of the haplotypes detected in cases and
controls of European and Asian ancestry, respectively. In Eur-
opeans, the most frequent haplotype and the only one associated
with any of the tested outcomes was the ancestral haplotype 8.1
(AH8.1) (~6 %). AH8.1 contains class I and class II HLA alleles
(A*0101 - B*0801 - C*0701 - DRB1*0301 - DQB1*0201 -
DQA1*0501) and showed increased risk for SCC in Europeans
(Table 2; Supplementary Fig. 1a; Supplementary Fig. 2). Condi-
tional analyses considering AH8.1 and HLA-DQB1 *06 in the
same model, revealed the independence of both effects (Table 2).
However, no signiﬁcant differences were detected in haplotype
frequencies for any of the outcomes for Asians.
Analysis of polymorphic amino acid positions and best model
selection. Although we identiﬁed a HLA haplotype and a 2-digit
allele group independently associated with SCC in Europeans we
aimed to answer the more reﬁned question as to whether the
association within the MHC resides with HLA alleles only, amino
acids only, or a combination of both HLA alleles and amino acids.
To answer this, we searched for the best combination of amino
acids and/or HLA alleles that explained the HLA haplotype
Table 2 Top associations of the HLA alleles with squamous cell carcinoma of European ancestry
Locus HLA variant Frequency Unconditional analysisa Model including AH8.1+HLA-
DQB1*06
Controlsc Casesc OR (95% CI) P value OR (95% CI) P value
AH 8.1 A1-B8-DR3-DQ2 0.06 0.07 1.30 (1.18-1.42) 4.78 × 10−08 1.24 (1.14–1.37) 2.13 × 10−06
HLA-A 01:01 0.15 0.17 1.18 (1.10-1.25) 9.36 × 10−07
HLA-C 07:01 0.15 0.17 1.17 (1.10-1.25) 5.53 × 10−07
HLA-B 08:01 0.10 0.12 1.25 (1.16-1.34) 9.01 × 10−09
HLA-DRB1 03:01 0.11 0.14 1.25 (1.16-1.34) 6.38 × 10−10
HLA-DQA1 05:01 0.20 0.29 1.18 (1.12-1.24) 1.33 × 10−09
HLA-DQB1 02:01 0.11 0.14 1.25 (1.17-1.34) 4.45 × 10−10
HLA-DQB1 06 globalb 0.24 0.21 0.85 (0.80-0.90) 3.05 × 10−08 0.86 (0.78-0.91) 9.96 × 10−08
06:01 0.01 0.01 0.87 (0.67-1.12) 0.3
06:02 0.12 0.10 0.90 (0.83-0.97) 0.007
06:03 0.07 0.06 0.84 (0.76-0.93) 5.06 × 10−04
06:04 0.04 0.03 0.86 (0.75-0.99) 0.03
06:09 0.009 0.007 0.80 (0.61-1.06) 0.1
AH 8.1 ancestral haplotype 8.1, HLA human leucocyte antigen, OR odds ratio, 95% CI conﬁdence interval
aObtained from multivariate unconditional logistic regression assuming an additive genetic model with sex and principal components as covariates
bClassical two-digit allele accounting for the four digit alleles found (*0601,*0602,*0603,*0604,*0609)
c Number of samples included in the analysis: 4,581 cases and 15,439 controls
The study-wide signiﬁcant threshold was P= 6 × 10−6 (Bonferroni correction)
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independently on the 2-digit allele group associated with SCC.
Our model selection criterion was the Bayesian Information
Criterion (BIC) since this has a heavy penalty for variable
inclusion. However, the results did not differ from those obtained
with the Akaike Information Criterion (AIC), a model-choice that
uses a weaker penalty (when sample sizes are large) than does the
BIC for the inclusion of variables.
As starting point, we ran an unconditional logistic regression
(see Materials and methods) for each of the amino acids of the
HLA genes and then searched for the best model from individual
HLA allele or amino acid using the BIC criterion. We observed
the most signiﬁcant associations at HLA-B, HLA-DRB1 and
HLA-DQB1 genes in Europeans.
HLA-B and HLA-DRB1 amino acids effects at Asp-9 (tagging
HLA-B*0801), Thr-163 and Asp-156 in B and Lys-71, Arg-74 and
Tyr-26 in DRB1 are located in protein binding grooves and part
of the AH8.1 HLA alleles, which adds functional relevance to our
data (Table 2, Fig. 3, Supplementary Table 4). Thr-163 and Arg-
74 individual models were the ones that best explained the data in
HLA-B and HLA-DRB1, respectively, as they presented the
lowest BIC value.
Amino acids associated in HLA-DQB1 were shared exclusively
by HLA-DQB1*06 molecules, i.e., not present in any other allele
in HLA-DQB1 detected in the analyzed samples. As these were
not located in protein binding grooves or any potential regulatory
function and both two-digit allele and amino acid individual
models showed similar support, we used HLA-DQB1*06 in
subsequent analysis (Supplementary Table 4).
The following variables were consistently included in the
combined models: B-Asp-9, B-Thr-163, B-Asp-156, HLA-B*0801,
DRB1-Lys-71, DRB1-Arg-74 and DRB1-Tyr-26, HLA-
DRB1*0301 and HLA-DQB1*06. Table 4 displays the combined
models with the best ﬁt to the data from this search using a
stepwise conditional logistic regression approach. There is some
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Fig. 2 Asian regional association plots of variants in the MHC region and lung cancer overall and major histologies (a–c); plots of stepwise conditional
analyses for lung adenocarcinoma (b. 1–b. 4). Each panel on the left shows the association plot for each analysis a lung cancer overall, b adenocarcinoma, c
squamous cell carcinoma. The association for each locus used for conditioning is shown in green in each panel on the right (b. 1) unconditioned, (b. 2)
conditioned on HLA-DQB1*0401, (b. 3) conditioned on HLA-DQB1*0401 and HLA-DRB1*0701, (b. 4) conditioned on HLA-DQB1*0401, HLA-DRB1*0701
and rs2256919 (SNP within HLA-A). Detailed association results in Table 3 and Supplementary Figure 1. Circles represent –log10 (P values) for each
binary marker using the imputed allelic dosage (between 0 and 2). The dashed black horizontal lines represent the study-wide signiﬁcant threshold of
P= 6 × 10−6. The physical positions of HLA genes on chromosome 6 are shown at the bottom. The color of the circles indicates the type of marker; light
blue—SNPs, green—classical HLA alleles, and red—amino acid polymorphisms of the HLA genes
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uncertainty as to the best model that relates to whether we ﬁnd
evidence of a three signal model at B-Thr-163, DRB1-Arg-74 and
HLA-DQB1*06 (model B), or just two signals at B-Thr-163 and
HLA-DQB1*06 (model C). However, DRB1-Arg-74 does not
seem to be an independent effect on B-Thr-163 since the effect
was not signiﬁcant and weaker within model B (OR= 1.11; p=
8.87 × 10−3), whereas the effect was stronger and signiﬁcant in
model D (OR= 1.19; p= 13 × 10−7) and in the individual model
(OR= 1.25; p= 13 × 10−8). Accordingly, model C was consid-
ered the best model ﬁtting the data. This implies that the amino
acid Thr-163 in HLA-B*0801 is sufﬁcient to explain the risk in the
AH8.1 haplotype for lung SCC in Europeans (Table 2; Table 4;
Supplementary Table 4; Fig. 3a).
In Asians, the most relevant amino acid positions for AD risk
were Ala-104 and Glu-98 (in tight LD, r2= 1) in HLA-DRB1 and
Leu-23 in HLA-DQB1 (Supplementary Table 5); their individual
models ﬁtted the data as well as HLA-DRB1*0701 and HLA-
DQB1*0401 alleles (Supplementary Table 5). However, when the
amino acids were included instead of alleles the model had no
support (Supplementary Table 6). In addition, these amino acids
were not located in the binding groove of the corresponding
molecules, thus a priori there is no functional relevance behind or
motivation for considering these amino acid positions over the
alleles as the best variants to explain the data.
Asian replication and meta-analyses. In order to give more
reliability to Asian results we included an additional set of
8,537 samples obtained from published GWAs5. This is a mul-
ticenter collection of non-smoking women that serves as a
replication collection as far as none of the hits were dependent on
smoking status or gender in the discovery phase (Supplementary
Fig. 1, Supplementary Tables 8 and 9). Therefore, we considered
it reasonable to meta-analyze both Asian datasets and then extend
our comparison between ethnicities.
In Asians from Lan et al., we did not observed any associations
in the overall analysis (Supplementary Fig. 4a). As in the ﬁrst
phase, after stratifying by major histologies we observed the top
association signals for lung AD (Supplementary Fig. 4b) and none
for SCC (Supplementary Fig. 4c).The T allele of rs2856688
located in an intergenic region within HLA class II was the top
associated marker. As this SNP was highly correlated with an
amino acid change resulting in a Ala-104 in HLA-DRB1*0701
and HLA-DRB1*0401 (r2= 0.95), we used this amino acid in
subsequent steps. After conditioning on classical HLA-DQB1
Ala-104 no additional variants remained associated with AD risk
with a signiﬁcance threshold (conditioned P > 6 × 10−6; Supple-
mentary Figure 4b. 2).
To gain insights into modest signals of association, we
combined the imputed results of the Asian Oncoarray and Lan
et al. using a random-effect meta-analysis approach. Results from
top Asian associated variants are displayed in Table 5. There is a
modest yet signiﬁcant heterogeneity between the studies, with
results from Oncoarray present stronger effects, even for the
variant originally reported in Lan et al. (Ala104/Ser104 can be
consider a surrogate (r2= 0.99) of this variant, rs2395185). The
two main HLA effects detected in Asian Oncoarray analysis, in
HLA-DQB1 and HLA DRB1, exceed the threshold of signiﬁcant
in the combined analysis showing a consistence with the results of
the ﬁrst phase. The HLA-A intronic SNP rs2256919 was not
however replicated.
Discussion
We have performed a comprehensive association analysis of HLA
alleles, SNPs and polymorphic amino acid sites that identiﬁed
several independent effects and their most likely causal variants
that lead to the association of the MHC with lung cancer in
Europeans and in Asians. In addition, our results suggest that the
genetic risk of the MHC region on lung cancer is different
between Asian and European populations.
Regarding the European data, the key ﬁndings are the AH8.1
haplotype association with SCC and a second independent signal
involving several HLA-DQB1*06 alleles. The main signal driving
the AH8.1 effect mapped to the HLA-B*0801 amino acid position
163 located in the protein binding groove.
In relation with previous ﬁndings, our analyses reﬁned the
association within BAG6/BAT3 susceptibility region encompass-
ing rs3117582. This variant is in high LD (r2= 0.76) with
HLAB*0801, therefore within AH8.1, and was reported as asso-
ciated with SCC in the largest lung cancer GWAs published to
date3,4. It was not certain whether these genes themselves or
others in linkage disequilibrium (LD) were primarily responsible
for these ﬁndings. Here, we demonstrate that the presence of a
threonine in the amino acid position 163 of HLA-B*0801
accounts for the main part of this effect as it ﬁtted the data in the
conditional model and it has biological signiﬁcance. However,
alleles within AH8.1 are in strong (but incomplete) LD19. For that
reason we can’t exclude additional loci within the haplotype
supporting or contributing additively to risk as probably is hap-
pening with the amino acid position 74 in HLA-DRB1*0301, also
located in the protein binding groove.
AH8.1 is a well-known Caucasian haplotype commonly asso-
ciated with immune-mediated diseases19–21. Typically deﬁned by
A*0101 - B*0801 - C*0701 - DRB1*0301 - DQB1*0201 -
DQA1*0501, it is the second longest haplotype identiﬁed within
the human genome. As it is common and stable in Caucasians, it
might have been advantageous in past environments, resistant to
recombination and positively selected over the time19. Similar
genetic associations reported for several autoimmune diseases
suggest common mechanisms of immune dysregulation21,22. The
amino acid position 163 in HLA-B is a functionally important
residue for TCR recognition and is also associated with TCR
Table 3 Top associations of the HLA alleles with adenocarcinoma of Asian ancestry
Locus Variant Frequency Unconditional analysisa Model including HLA-DQB1 *0401
+HLA-DRB1*0701+ rs2256919
Controlsb Casesb OR (95% CI) P value OR (95%CI) P value
HLA-DQB1 04:01 0.06 0.09 1.67 (1.35-2.05) 1.59 × 10−06 1.73 (1.41-2.14) 2.85 × 10−07
HLA-DRB1 07:01 0.05 0.09 1.62 (1.31-2.01) 5.48 × 10−06 1.63 (1.32-2.03) 5.34 × 10−06
HLA_A (intronic) rs2256919 0.44 0.38 0.75 (0.67-0.83) 1.75 × 10−07 0.76 (0.68-0.85) 8.92 × 10−07
HLA human leucocyte antigen, OR odds ratio, 95% CI conﬁdence interval
a Obtained from multivariate unconditional logistic regression assuming an additive genetic model with sex and principal components as covariates
b Number of samples included in the analysis: 1192 cases and 1656 controls
The study-wide signiﬁcant threshold was P= 6 × 10−6 (Bonferroni correction)
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expression23. Future functional analyses are needed to conﬁrm
the impact of our ﬁndings.
The HLA-DQB1*06 allele group showed a protective effect
independent of AH8.1. This association is based in two amino
acid positions (125 and 87) common to DQB1*06 4-digit alleles
(HLA-DQB1*0601, HLA-DQB1*0602, HLA-DQB1*0603, HLA-
DQB1*0604 and HLA-DQB1*0609) but not present in any other
DQB1 alleles detected here. It is possible that one of them is
driving the effect and the other is just in tight LD (R2= 0.78).
Alternatively, there may be a joint effect involving both amino
acids, driven by combined selection. This is plausible given the
important role of natural selection in the MHC22,24, even if these
are not in a clear functional physical location. The allele showing
the strongest association trend within DQB1*06 group is HLA-
DQB1*0603, part of the HLA class II haplotype HLA-
DRB1*1301–HLA-DQA1*0103–HLA-DQB1*0603 (in tight LD in
Europeans, r2 > 0.9) and associated with head and neck14 and
cervical cancer15, both squamous cell carcinomas linked to HPV
infection. For lung SCC this haplotype showed a trend of asso-
ciation with the same protective effect as in the HPV associated
cancers (Supplementary Table 14).
In contrast, in the Asians Oncoarray analysis we only observed
associations between HLA class II alleles and risk of lung ade-
nocarcinoma. We observed two independent HLA allele effects
increasing risk, HLA-DQB1*0401 and HLA-DRB1*0701, as well as
a protective intronic SNP in HLA-A (rs2256919). A potential
limitation of our study is the relatively modest sample size of the
Asian data set, compared with the European population. How-
ever, in the replication phase, we observed two of the three
independent HLA allele effects that were described in the ﬁrst
phase. One is represented by the four-digit allele HLA-
DQB1*0401 as in the discovery, and the other is better explained
by the association of Ala-104/Glu-98/Gln-10, part of HLA-
DRB1*0701 and HLA-DRB1*0401 protein sequence. This is the
same effect as the one described by Lan et al. in the intergenic
region in 6p21.32 (rs2395185) as all, SNP and amino acids
changes, are in tight LD (r2= 0.99). We could not conﬁrm the
association of the intronic SNP in HLA-A (rs2256919).
We also observed no overlap between Asian and European hits.
While we cannot rule out the possibility that some of the
observed differences could be due to the lack of power in the
Asian collection, it is possible that differences in the spectrum of
antigens in the two populations might introduce changes in
which alleles might play the important role in disease suscept-
ibility within each population. However, prevalence of never
smokers is another important difference between the Asian and
European data sets. While we consider it beyond doubt that Asian
HLA associations are independent on smoking, especially as we
have replicated our initial ﬁndings in nonsmoking Asian women,
is true that the proportion of non-smokers in Asian AD (469/
1192; 39%) is higher than in European AD (1004/7088; 14%) and
this could represent a problem if there is a dependency on
smoking. Despite this, we did not see the association in European
AD non-smokers even though the absolute number of never-
smokers among European AC cases was greater than among
Asians, and we had enough power to detect the effects shown in
Asian AD.
In summary, this evidence suggests a different aetiological role
for the MHC by population and by histology which points to
different exposures or mechanisms interacting with HLA. These
differences are clear for AD; however differences between ethni-
cities for SCC still need conﬁrmation. Taken together, our ﬁnd-
ings enhance the role of HLA variants in the immune
pathogenesis of lung cancer, and may also have implications for
cancer immunotherapies targeting the HLA antigen presentation
pathway16,25,26.
Methods
Sample collections and genotypes. Participants were of either European or Asian
ethnicity and came from 30 case-control studies that were included in the
OncoArray study, and part of the Transdisciplinary Research of Cancer in Lung of
the International Lung Cancer Consortium (TRICL-ILCCO) and the Lung Cancer
Cohort Consortium (LC3) (Supplementary Table 1). After quality control, the
European ethnicity series included 18,924 lung cancer cases and 15,439 controls,
whilst the Asians series comprised 2324 cases and 1656 controls (Table 1).
Informed consent was obtained for all participants, and studies were approved by
respective institutional review boards.
For all samples, we had access to genome-wide SNP data at individual level
from OncoArray genotyping platform27. The Illumina OncoArray custom was
designed for cancer studies by the OncoArray Consortium, part of the Genetic
Associations and Mechanisms in Oncology (GAME-ON) Network that includes
ﬁne-mapping of common cancer susceptibility loci with special emphasis on HLA
region among others. Oncoarray genotyping and genotype quality controls
procedure were done in the context of a large lung cancer genome-wide study using
the OncoArray platform4. Brieﬂy, genotype calls and quality control ﬁlters were
made by the Dartmouth team in GenomeStudio software (Illumina) using a
standardized cluster ﬁle for OncoArray. Standard quality control procedures were
163(Thr)
1.2 (1.14–1.26)
p - val=1.30E–11
9(Asp)
1.25 (1.16–1.34)
p - val=6.86E–09
156(Asp)
1.17 (1.11–1.24)
p - val=2.76E–08
a b
26(Tyr)
1.22 (1.14–1.31)
p - val=7.39E–09
74(Arg)
1.25 (1.16–1.34)
p - val=7.27E–10
71(Lys)
1.18 (1.12–1.25)
p - val=1.38E–08
Fig. 3 Three-dimensional ribbon models for the HLA-B (a) and HLA-DR (b) proteins. These structures are based on Protein Data Bank entries 2bvp and
3pdo, respectively, with a direct view of the peptide-binding groove. Key amino acid positions identiﬁed by unconditioned association analyses (squamous
cell carcinoma of European ancestry) are highlighted. This ﬁgure was prepared using UCSF Chimera (see URL)
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used to exclude underperforming genotyping assays (judged by success rate,
genotype distributions deviated from that expected by Hardy Weinberg
equilibrium). Additionally, individuals with low genotyping success rate (<95%)
and individuals with a genetically inferred gender by X and Y markers did not
match that reported gender, or had excess identity by descent sharing relative to
other samples, were excluded. Principal components analysis (PCA) was done
using FlashPCA3 and identiﬁed 10 and 3 signiﬁcant eigenvectors on the European
and the Asian dataset, respectively, that were used as covariates in the association
analyses. PCA plots are displayed in Supplementary Fig. 5. Furthermore,
generalized linear models showed that of the eigenvectors were signiﬁcantly
associated with the study of recruitment either in Asian or in European series (p-
value: < 10−16). Therefore, we have used eigenvectors in lieu of study to better
adjust for genetic/ethnic origin.
An additional Asian series including 4962 lung cancer cases and 3845 controls
was downloaded from DbGaP5 (dbGaP reference: phs000716.v1.p1) and was used
as a replication collection of the initial Asian results. Genome-wide data came from
two sources in this study but we only used genotypes from the Illumina 660W SNP
microarray as this was the source of the majority of the samples and of the same
Asian origin. On top of the quality controls done5, 270 duplicated samples were
excluded. To account for potential population stratiﬁcation, we performed PCA in
EIGENSTRAT28 using approximately 10,000 common markers in low LD (r2 <
0.004, minor allele frequency (MAF) > 0.05). Subsequently, we derived the
7 signiﬁcant eigenvectors to adjust association analyses. PCA plots are displayed in
Supplementary Fig. 5. Supplementary Table 7 shows demographic characteristics of
the ﬁnal replication set 4,741 lung cancer cases and 3,796 controls, after quality
controls.
Imputation of the HLA system. Taking advantage of the high OncoArray SNP
coverage in the HLA region, we used the genotyping data from 25 to 35 Kb at
chromosome 6 (NCBI build 37) obtained to impute classical two and four digit
HLA alleles and amino acid polymorphisms of the HLA genes along with the SNPs
that were not directly genotyped.
For Europeans, we imputed HLA variants using the reference data collected by
the Type 1 Diabetes Genetics Consortium (T1DGC)6,29. This is a panel composed
of 5,225 individuals of European origin with genotyping data for 8,534 SNPs and
424 classical HLA alleles of class I (HLA-A, HLA-B and HLA-C) and class II (HLA-
DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1 and HLA-DPA1) genes. For Asians,
we used the Pan-Asian reference panel30,31 which contains genotype data for 8,245
SNPs and 273 classical HLA alleles tagging the entire MHC, as described above, in
530 unrelated individuals of Asian descent.
Imputation process was performed with the SNP2HLA v1.0.3 package using
Beagle software32,33 (http://www.broadinstitute.org/mpg/snp2hla). It was
conducted separately for each ethnic group and we imputed cases and controls
together in randomized groups of approximately 1000 individuals. We applied
post-imputation QC criteria of R2 < 0.3 for excluding variants in the association
analysis.
Imputation validation. To conﬁrm imputed HLA alleles, we re-imputed34 a
random 10% subset of the samples (3000 European samples and 1000 Asian
samples from Oncoarray) using HIBAG18,which employs another pre-trained
referenced panel and a different statistical method based on multiple expectation-
maximization-based classiﬁers to estimate the likelihood of HLA alleles (http://
www.biostat.washington.edu/~bsweir/HIBAG/). Previous studies comparing the
accuracy of HIBAG and SNP2HLA (among others imputation methods) to
sequence data, concluded that they are the most robust programs with respect to
maintaining accuracy35,36. In order to assess the accuracy of the imputation, we
compared the imputed data for HLA alleles of class I (HLA-A, HLA-B and HLA-C)
and class II (HLA-DRB1, HLA-DQB1, HLA-DQA1), of those HLA genotypes
obtained in the same individuals with the two methods described above. Two
parameters were considered for this comparison 1) a correlation coefﬁcient (r),
which is a measure of the reliability of the frequencies, and 2) the accuracy, to
establish reproducibility of the typing in each individual, as described elsewhere37.
We also performed a laboratory validation genotyping to conﬁrm array imputed
dosages of the associated variants using another genotyping platform Affymetrix
Axiom exome array17 in a subset of 5,742 individuals from the European series. We
considered the associated variants that achieved the study signiﬁcance in Europeans.
For these loci, the sentinel variant (or correlated proxy variant) was also genotyped
on the custom Affymetrix Axiom exome array. We therefore considered the
concordance between the OncoArray genotypes and the Affymetric array for these
variants in the 5,742 individuals where genotyping was available for both platforms.
Supplementary Table 11 describes the satisfactory concordance between OncoArray
(imputation) genotypes and the validation genotypes.
Analysis across the MHC region. All the tested HLA variants were deﬁned as
binary markers as follow: for biallelic SNPs, classical HLA alleles and binary amino
acid positions, the effect allele or variant was the minor allele, the presence of the
HLA allele or the presence of the less frequent amino acid. For multi-allelic amino
acid positions we deﬁned composite markers where each possible individual allele
and combination of alleles was tested for association.
To test for association within the HLA region and given the ancestral variation
of our study, we evaluated associations separately for each ethnicity (European and
Asian). For each marker we used dosages, which take uncertainty in imputation
into account, in multivariate unconditional logistic regression models under a log-
additive genetic model controlling for sex and principal components (as was
described above). We assessed the association between the described variants and
lung cancer risk, as well as predominant histological types and smoking behaviour.
We set a study-wide signiﬁcance threshold of P= 6 × 10−6, on the basis of the
highest total number of genotyped SNPs, as well as imputed SNPs, HLA alleles and
amino acid variants that were included in the analyses after passing QC for
Europeans (0.05/8,291) and Asians (0.05/5,504). The number of markers that
passed QC in the Asian series is less but we maintained in the Asian analysis the
more conservative p-value cut-off adopted for Europeans. This correction far
exceed number of independent test expected within this region given its high
linkage disequilibrium, and it can be considered a very conservative p-value.
To assess whether there were independent effects outside of the main associated
loci, we used a conditional additive logistic regression approach to test all markers
across the MHC. In order to explore whether any of the signiﬁcant variant
identiﬁed in this process have any potential regulatory function if they are not in a
critical location, we used the online tool HaploReg v4.138 to conﬁrm location of
each SNP in relation to annotated protein-coding genes and/or non-coding
regulatory elements. As a ﬁrst step, we included HLA alleles as covariates when
they or their tag-SNPs (not annotated as functional) appeared as the best associated
Table 4 HLA alleles and amino acids contained in the best models obtained for SCC in Europeans judged by the BIC criterion
Model Locus OR (95%CI) P value BIC BIC difi
A
AH8.1+HLA-DQB1 *06 21605 +14
AH8.1 1.24 (1.14-1.37) 2.13 × 10−6
HLA-DQB1 *06 0.86 (0.78-0.91) 9.96 × 10−8
B
B-Thr163+DRB1-Arg74+HLA-DQB1 *06 21594 + 3
B(163) 1.13 (1.07-1.20) 1.68 × 10−5
DRB1(74) 1.11 (1.03-1.20) 8.87 × 10−3
HLA-DQB1 *06 0.87 (0.82-0.92) 1.15 × 10−6
C
B-Thr163+HLA-DQB1 *06 21591 0
B(163) 1.17 (1.11-1.23) 1.83 × 10−9
HLA-DQB1 *06 0.86 (0.81-0.91) 8.47 × 10−8
D
DRB1-Arg74+HLA-DQB1 *06 21603 +12
DRB1(74) 1.19 (1.11-1.28) 6.59 × 10−7
HLA-DQB1 *06 0.87 (0.82-0.91) 8.10 × 10−7
BIC Bayesian information criterion, HLA human leukocyte antigen
c Number of samples included in the analyses: 4581 cases and 15,439 controls
i models having their BIC within:+ 1–2 of the minimum have substantial support;+ 4–7 of the minimum have considerably less support; > 10 above the minimum have either essentially no support
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markers. If we identiﬁed other independently associated markers, we included
them also as covariates in subsequent conditional analyses. All statistical analyses
were performed in R version 3.2.3 (https://www.r-project.org/).
To help the interpretation of the results and the comparison between
ethnicities, supplementary tables 12 and 13 display statistical power calculations for
both populations but also imputation probabilities for the associated variants.
Meta-analysis of Asian datasets. We combined the results of Asian Oncoarray
and Lan et al. studies using GWAMA (Genome-Wide Association Meta-Analysis)39
software to perform random-effect meta-analyses. The software incorporates error
trapping, which facilities to identify strand alignment errors and allele ﬂipping, and
performs tests of heterogeneity of effects between studies.
Haplotype inference, visualization and association analyses. The results of
HLA alleles and SNPs might not translate directly to a single locus as a result of the
extended linkage disequilibrium (LD) known to exist in the MHC; it is possible that
markers that seem to be acting independently with respect to genotype risk could
be on a shared haplotype (http://www.ebi.ac.uk/ipd/imgt/hla/). We search for
signiﬁcant combination of HLA alleles using Haplo.stats package v.1.7.7 (https://
cran.r-project.org/web/packages/haplo.stats/index.html) implemented in R soft-
ware to generate population-based haplotypes from phased genotypes obtained
from the imputed data. Haplo.stats uses the expectation-maximization algorithm
and progressively inserts batches of loci into haplotypes. We inferred haplotypes
frequencies within class I alleles, class II and along the MHC (class I and class II)
for Asians and Europeans. Then, using the statistical framework and covariates
deﬁned above, we individually tested each of the haplotypes for association with
lung cancer overall and in the subgroups described.
HLA linkage disequilibrium (LD) maps were obtained using Disentangler
(http://kumasakanatsuhiko.jp/projects/disentangler/), a graphical tool suitable for
visualization of haplotype conﬁgurations across multiallelic genetic markers for
which typical triangular heat maps with LD indices will not work. Disentangler also
applies expectation-maximization algorithms to estimate the haplotype frequencies
between adjacent markers, and it uses then this information to determine the order
of the alleles for each marker and the number of crossing lines between adjacent
markers40,41. We created separate population-speciﬁc maps for cases and controls,
using the whole collection for Asians and a randomized set of 5,000 cases and 5,000
controls for Europeans.
Unravelling candidate functional variants. Using the independently associated
HLA alleles and/or haplotypes, their signiﬁcant amino acids and SNPs, we searched
for the best overall HLA model. First, we used a forward selection stepwise
regression of signiﬁcant amino acids within the independently associated regions.
For each gene or region we looked for the set of signiﬁcant amino acid positions
and we deﬁned the classical alleles with consistent residues at those positions. We
also included as covariates in these risk models the independent markers previously
identiﬁed. The aim was to ﬁnd the best set of amino acids and/or HLA alleles that
were independently associated with lung cancer as judged by the lowest AIC
(Akaike Information Criterion) and BIC (Bayesian Information Criterion)42,43.
Ribbon representations of the associated HLA molecules were constructed with
the UCSF Chimera software44 to locate signiﬁcant amino acids in the tri-
dimensional structure of the protein (http://www.cgl.ucsf.edu/chimera/). We also
used the online tool HaploReg v4.138 to conﬁrm location of each SNP in relation to
annotated protein-coding genes and non-coding regulatory elements (http://
archive.broadinstitute.org/mammals/haploreg/haploreg.php).
Data availability
Genotype data for the lung cancer OncoArray study have been deposited at the database
of Genotypes and Phenotypes (dbGaP) under accession phs001273.v1.p1. The Asian
replication dataset was downloaded from dbGaP under accession phs000716.v1.p1.
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